This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cohen, N. A. Articles by Hilton, J. Search for Related Content PubMed PubMed Citation Articles by Cohen, N. A. Articles by Hilton, J.

Interaction of N,N',N''-Triethylenethiophosphoramide and N,N',N''-Triethylenephosphoramide with Cellular DNA¹

Division of Developmental Therapeutics, University of Maryland Cancer Center [N. A. C., M. J. E., S. W. S., B. A., B. E. W., S. P., D. D., R.], and Division of Medical Oncology, Department of Medicine [M. J. E., D. D. R.], University of Maryland School of Medicine, Baltimore, Maryland 21201; and Pharmacology Laboratory [J. H.], The Johns Hopkins Oncology Center, Baltimore, Maryland 21205

The antineoplastic agents N,N',N''-triethylenethiophosphoramide (thioTEPA) and N,N',N''-triethylenephosphoramide (TEPA) were studied for their interaction with the DNA of L1210 cells in the presence and absence of rat hepatic microsomes and NADPH. Alkaline elution was used to study 3 types of DNA lesions. When L1210 cells were incubated with thioTEPA alone, or with thioTEPA in the presence of microsomes and NADPH, no single-strand breaks were detected. However, incubation of L1210 cells for 2 h with thioTEPA, at concentrations 100 µM, caused a dose-dependent increase in interstrand cross-linking that reached a maximum by 2 h after drug exposure. In the presence of rat hepatic microsomes and NADPH, this cross-linking was eliminated, but a different DNA lesion, alkali-labile sites, was produced. These alkali-labile sites were partially reparable with maximum repair achieved by 2 h after removal of drug. ThioTEPA was >85% consumed by the microsomal incubation conditions employed, and TEPA was the only product of the microsomal metabolism of thioTEPA. Alkaline elution studies of L1210 cells that had been incubated with TEPA, alone or in the presence of microsomes and NADPH, demonstrated an elution pattern identical to that produced by thioTEPA in the presence of microsomes and NADPH. Lymphoblastoid cell lines derived from patients with Fanconi's anemia were far more sensitive to thioTEPA and mechlorethamine hydrochloride than were lymphoblasts derived from normal humans, but this hypersensitivity was not noted with TEPA or bleomycin. This is consistent with the known hypersensitivity of cells from patients with Fanconi's anemia to agents that produce interstrand cross-links and with the alkaline elution studies described above. In contrast, lymphoblastoid cell lines derived from patients with ataxia telangiectasia were no more sensitive to thioTEPA than were lymphoblasts derived from normal humans but were far more sensitive to bleomycin. One of these cell lines proved hypersensitive to TEPA, whereas the other was no more sensitive to TEPA than were lymphoblasts from normal humans. Our data imply that thioTEPA produces interstrand cross-links but that TEPA, the primary metabolite of thioTEPA, produces DNA lesions that are alkali labile.

¹ Supported in part by American Cancer Society Grant CH-412 and the Bressler Research Fund.

² To whom requests for reprints should be addressed, at University of Maryland Cancer Center, 655 W. Baltimore, St., Baltimore, MD 21201.

Received 1/14/91. Accepted 6/ 6/91.

This article has been cited by other articles:

				T.-C. Chou Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies Pharmacol. Rev., September 1, 2006; 58(3): 621 - 681. [Abstract] [Full Text] [PDF]

				M. Kobune, Y. Xu, C. Baum, M. R. Kelley, and D. A. Williams Retrovirus-mediated Expression of the Base Excision Repair Proteins, Formamidopyrimidine DNA Glycosylase or Human Oxoguanine DNA Glycosylase, Protects Hematopoietic Cells from N,N',N''-Triethylenethiophosphoramide (thioTEPA)-induced Toxicity in Vitro and in Vivo Cancer Res., July 1, 2001; 61(13): 5116 - 5125. [Abstract] [Full Text] [PDF]

				Y. Xu, W. K. Hansen, T. A. Rosenquist, D. A. Williams, M. Limp-Foster, and M. R. Kelley Protection of Mammalian Cells against Chemotherapeutic Agents Thiotepa, 1,3-N,N'-Bis(2-chloroethyl)-N-nitrosourea, and Mafosfamide Using the DNA Base Excision Repair Genes Fpg and {alpha}-hOgg1: Implications for Protective Gene Therapy Applications J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 825 - 831. [Abstract] [Full Text]

				T. Chen, A. Aidoo, R. A. Mittelstaedt, D. A. Casciano, and R. H. Heflich Hprt mutant frequency and molecular analysis of Hprt mutations in Fischer 344 rats treated with thiotepa Carcinogenesis, February 1, 1999; 20(2): 269 - 277. [Abstract] [Full Text] [PDF]